



Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria

WALTHAM, Mass., Sept. 19, 2014 – Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, issued the following statement today in support of President Barack Obama's Executive Order Combating Antibiotic-Resistant Bacteria.

"As the global leader in rapid diagnostics for infectious disease, we commend the President for establishing a national strategy to address the serious threat of antibiotic resistance. We look forward to continuing to work with the Administration on initiatives to promote the development of rapid point-of-care tests that, in turn, help reduce the misuse of antibiotics and unnecessary health care spending," said Avi Pelossof, Alere Global President, Infectious Disease.

The Executive Order signed by the President yesterday directs Federal departments and agencies to implement a new national strategy to combat antibiotic-resistant bacteria and to address recommendations in a report by the President's Council of Advisors on Science and Technology (PCAST). For more information on the Executive Order, go to <http://www.whitehouse.gov/the-press-office/2014/09/18/executive-order-combating-antibiotic-resistant-bacteria>.

In partnership with the Alliance for the Prudent Use of Antibiotics (APUA), Alere has established [Test. Target. Treat.](#)TM, an antimicrobial stewardship initiative that provides tools and diagnostic strategies to support clinicians and increase global awareness of antibiotic resistance and effective interventions.

About Alere

Alere's global leading rapid diagnostic products and services, as well as its new product development efforts, focus on infectious disease, cardiometabolic disease and toxicology. Alere is headquartered in Waltham, Massachusetts. For more information regarding Alere, please visit www.alere.com.

###

Media Contact:

Jackie Lustig
Director, Corporate Communications
Jackie.Lustig@alere.com
781.314.4009